Translate Bio Announces FDA Clinical Hold on Investigational New Drug Application (IND) for MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency

Stock Information for Translate Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Translate Bio Inc.

Translate Bio Appoints Pasquale (Pat) Sacco as Senior Vice President of Technical Operations
Translate Bio Granted U.S. Patent Relating to Messenger RNA (mRNA) Delivery
Translate Bio to Participate in Upcoming Investor Conferences
Translate Bio Announces Fourth Quarter and Full Year 2018 Financial Results and Reviews Recent Highlights
Translate Bio Announces Publication of Preclinical Data Demonstrating Efficacy of Systemic mRNA Delivery in Fabry Disease Model in the Journal Molecular Therapy
Translate Bio to Present at the 39th Annual Cowen and Company Healthcare Conference
Translate Bio Provides Updates on Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency Programs
Translate Bio to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.